Lupus

Clowse discussed findings from the phase 3 PHOENYCS GO trial presented at the 2024 ACR Convergence.

The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.

A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.

Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.

A study found that high ultraprocessed food consumption increases the risk of SLE by 56%, with an even higher risk for anti-dsDNA positive SLE at 105%.

The therapy demonstrated superior efficacy in combination with SOC over SOC alone.

Those with limited health literacy had higher disease activity and more SLE damage.

Other recent research found that having osteoarthritis increased the risk of developing carpal tunnel syndrome.

The study highlighted the potential role of shared decision-making in building trust in physicians among patients with SLE.

Vitamin D insufficiency was linked to reduced muscle strength, increased pain, higher disease activity, fatigue, and worsened disease outcomes.

A recent study provides some evidence of the ability to potentially reduce belimumab dose in a subset of patients with SLE.

Data presented at NKF Spring Clinical Meeting suggest events including myocardial infarction and stroke are more prevalent among patients with lupus in North America.

As disparate representation in pivotal research impacts the outcomes of common diseases like lupus, clinicians and researchers alike are working to foster trust and collaboration with more patients of color.

FDA approves label update for voclosporin (Lupkynis) in lupus nephritis, reflecting long-term AURORA data and new kidney function monitoring guidance.

Gut microbiota-based treatment relieved pain for patients with fibromyalgia.

Mohamed Cherry, MD, and Neil Kramer, MD, shed light on a phase 1 trial using CAR-T cell therapy for SLE and its potential implications for lupus treatment.

A groundbreaking phase 1 study using CAR-T cells to treat severe lupus highlights a collaborative effort between the Cellular Therapy Program and rheumatology programs to pioneer innovative patient care.

The Xist ribonucleoprotein (RNP) complex, linked to the XX sex chromosome complement, influences the susceptibility to autoimmunity.

The percentage of lymphocyte apoptosis in peripheral blood was significantly higher in patients with jSLE when compared with healthy controls.

A retrospective cohort analysis suggests the monoclonal antibody may help patients with SLE reduce their reliance on oral corticosteroids over 1 year after initiating treatment.

The progression toward more targeted, disease-modifying options for the historically difficult rheumatic disease made more headway in 2023.

Stacie Bell, PhD, highlights the lasting effects of childhood adversities in patients with pediatric lupus.

Stacie Bell, PhD, discusses the disagreement between adolescents and parents regarding how lupus impacts daily life.

Data from the phase 3 TULIP long-term extension trial support the favorable benefit-risk profile of anifrolumab-fnia demonstrated in previous trials.

Results provide the first clinical evidence to suggest that afimetoran may offer a benefit to patients with cutaneous lupus erythematosus.

Throughout 2023, interest in the application of CAR-T and other cell therapies to autoimmune disease skyrocketed, with a multitude of clinical trials being initiated by various companies.

Expert rheumatologists discuss current treatment options for lupus nephritis and emerging therapies with newer mechanisms of action.

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with CLE.

In this research presented at ACR 2023, a connection between antiphospholipid antibodies and a greater potential risk of cardiovascular disease was identified.

This research into improving quality measures for lupus patients was presented at ACR 2023 and funded by the CDC.